HiSiaddi is an innovative foreign trade service provider driven by dual engines of technology transformation and foreign trade services. We have established a service system formulated as "1+2+3+4=1" and can supply original factory goods of well-known brands for P29, the core intermediate of semaglutide. With over a decade of market experience and technological transformation cooperation with manufacturers, HiSiaddi possesses extensive experience addressing product compliance issues. Below is HiSiaddi’s case resolving compliance risks for P29, the core semaglutide intermediate.
For further inquiries on P29 product compliance issues, please contact HiSiaddi customer service.
The client is Swiss Pharma AG, a high-end biopharmaceutical company based in Zurich, Switzerland, specializing in R&D and manufacturing of GLP-1 innovative drugs and biological products supplied to high-end pharmaceutical markets across the EU, North America and worldwide. The company adopts zero tolerance for compliance risks and fully adheres to FDA, EMA, ICH Q7, GMP and REACH standards. Annual procurement volume of P29, the core semaglutide intermediate, is approximately 150 kg for commercial API production and new drug filings, classifying it as a typical high-end overseas client.
This is the client’s first procurement of P29 from China. Stringent European and American regulatory standards, uneven compliance document quality among domestic manufacturers, mismatched regulatory standards and audit-incompatible document formats created major obstacles. Three contacted manufacturers failed to provide complete compliance materials in one submission, with five core compliance hazards including missing DMF filings, incomplete GMP documents, missing impurity research reports, unfinished REACH registration and customs classification risks. These risks directly impacted product import customs clearance and EMA/FDA audits, prompting the client to entrust HiSiaddi with full risk inspection, compliance gap remediation, compliance system establishment and guaranteed smooth customs clearance and audits within 10 days.
HiSiaddi’s compliance team collaborated with top domestic pharmaceutical compliance institutions to conduct full-dimensional audits of the P29 manufacturer’s qualifications, documents, production systems and export workflows, identifying six critical compliance hard barriers that serve as key market access thresholds for European and American high-end markets:
The client’s products supply the US market and support new drug filings, mandating P29 suppliers to complete FDA Drug Master File (DMF) filings covering core data including production processes, quality control, impurity research and stability studies. Contacted manufacturers only provided basic COAs without DMF filings, preventing linkage to the client’s ANDA filings and creating severe registration risks.
EU regulations mandate Certificate of Suitability (CEP) or European Drug Master File (EDMF) for imported APIs and key intermediates, alongside official Chinese export pharmaceutical certificates complying with EU Directive 62. Manufacturers only supplied basic GMP certificates without CEP certification, incomplete EDMF core modules, insufficient impurity spectrum research and no official export certificates, making EMA on-site audit passage impossible.
European and American audits require complete, traceable ICH Q7-aligned GMP document systems including Batch Production Records (BPR), Batch Inspection Records (BIR), equipment validation, cleaning validation and personnel qualification files. Manufacturers had disorganized document versions, incomplete records, missing key parameters, no electronic batch records and expired validation reports, triggering severe data integrity risks and high likelihood of audit deficiencies.
As a polypeptide intermediate, P29 requires strict control of single impurities, total impurities, genotoxic impurities, residual solvents and endotoxins, supported by complete impurity spectra, structural identification, safety assessments and analytical method validation reports. Manufacturers only provided basic purity data without impurity structural identification, genotoxicity assessments, ICH Q3C-compliant residual solvent testing or validated endotoxin testing methods, failing EP/USP pharmacopoeia requirements.
EU REACH regulations mandate full REACH registration for all imported chemicals including pharmaceutical intermediates, with mandatory submission of substance information, exposure assessments and Safety Data Sheets (MSDS). Manufacturers lacked REACH registration, EU-standard MSDS and exposure assessment reports, risking cargo detention, fines and return upon arrival at EU ports.
P29 is a complex polypeptide pharmaceutical intermediate prone to HS code misclassification (29371900 / 29339900) and categorized as Class 9 hazardous goods due to trace residual solvents. Manufacturers adopted incorrect HS coding, failed to declare goods per IMDG rules, used non-compliant hazardous goods packaging and lacked hazardous goods packaging certificates, triggering customs rejection, cargo detention and delivery delays.
HiSiaddi assembled a dedicated cross-functional team integrating compliance, technical and customs specialists, collaborating with domestic FDA registration agencies, EU compliance firms, GMP audit companies and customs classification experts to develop a 7-day rapid rectification + long-term compliance maintenance plan addressing all six compliance risks item by item:
Select Chongqing Paijin Biotechnology, the only domestic P29 manufacturer with FDA DMF filing (No. 039617), as the core supplier, featuring a 3,000 L fermentation scale and 300 kg annual capacity with DMF files fully covering production, quality, impurity and stability modules. Coordinate the manufacturer to submit annual DMF updates and supplementary data to the FDA, linking the client’s API filing information to ensure active, valid DMF status directly usable for ANDA filings.
Assist the manufacturer in launching CEP certification applications while compiling EMA-compliant EDMF files focusing on four core modules: impurity spectrum research, process validation, stability data and analytical method validation. Coordinate with China NMPA to apply for EU export pharmaceutical certificates (WC certificates) complying with EU Directive 62 as mandatory official documents for EU customs clearance. All documents are fully compiled in English with factory stamps and QP signatures for direct submission during EMA audits.
Restructure complete GMP document systems aligned with ICH Q7 + EU GMP standards, including over 20 core SOPs, standardized batch production and inspection record templates, equipment validation reports, cleaning validation reports and personnel qualification archives. Standardize electronic batch record systems enabling real-time production data collection, automatic capture of critical non-tamperable parameters and full end-to-end traceability. Conduct mock EMA audits to remediate document deficiencies in advance, ensuring zero major or critical audit deficiencies.
Entrust authoritative laboratories including SGS and TÜV Germany to conduct full-item impurity testing, structural identification, genotoxicity assessments, ICH Q3C-compliant residual solvent testing and endotoxin analytical method validation for P29. Compile comprehensive impurity research reports confirming single impurity ≤0.08%, total impurities ≤0.4%, endotoxin <0.08 EU/mg and absence of genotoxic impurities, fully complying with EP 10.0 and USP 43 pharmacopoeia standards. Supply analytical method validation reports to guarantee accurate, reliable and repeatable test data.
Entrust local EU compliance institutions to complete P29 REACH registration (Registration No. 01-2119987654-32-0001) covering full substance identity, physicochemical properties, exposure assessment and safety measures. Compile EU-standard 16-section English MSDS specifying hazard classification, safe operation, storage & transportation and emergency response protocols. Supply REACH registration certificates, MSDS and safety exposure assessment reports for barrier-free EU customs clearance.
Collaborate with customs classification experts to confirm the accurate HS code for P29: 29371900 (aligned with General Administration of Customs classification guidelines). Classify P29 as Class 9 hazardous goods per IMDG Code, apply for hazardous goods packaging certificates and dangerous goods safety transport declarations. Adopt UN-standard hazardous goods packaging affixed with compliant hazard labels, UN numbers and leak-proof markings. Arrange professional hazardous goods customs brokers for pre-submission document review to ensure one-time declaration approval without rejection or detention.
Assign dedicated compliance specialists to liaise with clients and manufacturers for real-time synchronization of regulatory updates, document revisions and filing status. Conduct quarterly internal compliance inspections and annual mock audits to identify risks proactively. All compliance documents are uniformly archived in English with real-time updates for instant support during client audits and regulatory inspections.
· FDA DMF: Active filing with completed updates, directly usable for new drug filings
· EU compliance: CEP certification in progress, complete EDMF documents, approved WC certificates, EMA audit-ready
· GMP systems: Complete standardized documents, compliant records, full data integrity, passed mock audits
· Impurity safety: All test items qualified, EP/USP pharmacopoeia compliance, zero safety risks
· REACH registration: Completed registration, compliant MSDS, unobstructed EU market access
· Customs clearance compliance: Accurate classification, standardized hazardous goods declaration, compliant packaging, smooth customs clearance
The client submitted full compliance documents provided by HiSiaddi to pass the EMA on-site audit with zero major or critical deficiencies. Simultaneous FDA DMF linkage pre-review confirmed P29’s eligibility for direct use in the client’s US new drug filings without registration barriers.
The first 50 kg P29 shipment passed one-time Chinese export customs declaration and EU import customs clearance without detention, fines or delays, with delivery lead time controlled within 30 days fully matching the client’s production schedule.
Client feedback: "HiSiaddi thoroughly resolved our compliance pain points covering full workflows from DMF filings and GMP documents to impurity research, REACH registration, classification declarations and delivery. The team delivered professional, efficient and precise services helping us eliminate all European and American compliance risks and establish a safe, stable and compliant Chinese supply chain fully meeting the compliance standards of top Swiss pharmaceutical enterprises."
The client signed a 5-year exclusive compliance procurement agreement with HiSiaddi, raising annual procurement volume to 200 kg. HiSiaddi was also appointed the global strategic compliance partner responsible for full-process compliance audits, document preparation, audit support and customs clearance guarantee for all Chinese-sourced products including other semaglutide intermediates, protected amino acids and APIs.
Core pain points for overseas high-end pharmaceutical enterprises sourcing high-end polypeptide intermediates such as P29 include stringent European and American compliance requirements, domestic manufacturers’ compliance gaps, cross-regulatory standard discrepancies and audit-incompatible document formats. Compliance issues not only hinder customs clearance and delivery but also determine market access eligibility, new drug filing feasibility and audit passage outcomes for products. Violations may trigger catastrophic consequences including cargo return, fines, production shutdowns and failed registrations.
Leveraging a professional compliance team, extensive European and American regulatory experience, mature compliance resource networks and full-process solution capabilities, HiSiaddi successfully resolved the client’s six core compliance challenges:
1. Targeted compliant resource matching: Source manufacturers with valid FDA DMF filings to guarantee compliance at the source.
2. Full-dimensional document remediation: Cover DMF/CEP/EDMF/GMP/REACH full documentation aligned with European and American audit standards.
3. Dual technical & compliance assurance: Strengthen impurity research and safety assessments to guarantee pharmacopoeia-compliant product quality.
4. Zero-risk customs clearance compliance: Standardize classification, hazardous goods declaration and packaging for seamless cross-border logistics.
5. Long-term compliance maintenance: Establish dynamic compliance mechanisms to continuously address regulatory updates and audit demands.
This service not only helped the client eliminate market access barriers to European and American markets with zero compliance risks and stabilize supply chains to accelerate new drug filing progress but also set a benchmark for HiSiaddi, a Chinese enterprise, delivering full-process compliance solutions to overseas high-end pharmaceutical manufacturers. It facilitates high-end domestic polypeptide intermediates to integrate deeply into the global high-end pharmaceutical industrial chain with full regulatory compliance.
For further inquiries on P29 product compliance issues, please contact HiSiaddi customer service.
+86-13120989737 
info@hisiaddi.com 
English
